Abstracts Poster Abstracts - Dr Falk

78Evaluation of Ursofalk ® 's effect on hepatic haemodynamic parametersin treatment of patients with compensated liver cirrhosisMatcovschi Serghei, Tcaciuc Eugen, Matcovschi IrinaState Medical and Pharmaceutical University "Nicolae Testemitanu", Chair of InternalMedicine Nr. 5, Chisinau, MoldovaThe aim of our study was to evaluate the effect of the Ursofalk ® administration on thehepatic haemodynamic parameters in patients with compensated liver cirrhosis.Patients and methods: We studied 41 patients with liver cirrhosis of viral C etiology instage A (according to Child-Pugh score). All the patients were evaluated by duplexDoppler ultrasonography of portal system and hepatic artery before and after 1 monthof treatment. 29 patients received Ursofalk ® (750 mg daily) and 12 patients did notreceive Ursofalk ® (control group).Results: Ursofalk ® administration significantly decrease the diameter of the trunk of theportal vein with 9.9 ± 0.5% (p < 0.05), the diameter of the splein vein with 11.2 ± 0.7%(p < 0.05). The portal blood flow velocity in the trunk of the portal vein significantlyincrease with 10.3 ± 1.2% (p < 0.05). Was not discovered significantly change of theportal blood flow in the portal and splein veins (p > 0.05). Hepatic artery resistanceindex significantly decrease with 16.2 ± 3.1% (p < 0.05). In control group we did notobserve any significantly change (p > 0.05).Conclusion: Our study indicates that the administration of Ursofalk ® in patients withcompensated liver cirrhosis (class A by Child-Pugh) improves the hepatichaemodynamic, probably, because they contribute to decrease the intrahepaticresistance in cirrhotic patients.